Mayo Clinic and Kiyatec to collaborate on ovarian cancer care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MAYO CLINIC will collaborate with Kiyatec Inc. on technology platforms for ovarian cancer care. Mayo Clinic is enrolling patients in a study that uses patient-derived xenografts to generate living tumor samples specific to each enrolled ovarian cancer patient. The study assesses whether those samples can help determine which chemotherapy is most effective to treat that...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login